NCT03071068 - A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions

Diabetic RetinopathyMacular Edema

Interventions

DRUG

Anti-PlGF recombinant monoclonal antibody, 4mg dose

3 intravitreal injections of THR-317 4mg approximately 1 month apart

DRUG

Anti-PlGF recombinant monoclonal antibody, 8mg dose

3 intravitreal injections of THR-317 8mg approximately 1 month apart

Trial Locations (13)

Budapest

Budapest

Debrecen

Szeged

Pécs

Brno

Hradec Králové

Prague

Prague

Bratislava

Bratislava

Trenčín

Žilina